To address this question, Cerqueira-Silva et al. analysed the national disease surveillance and vaccination databases from Brazil to estimate the effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2 and Ad26.COV2.S in individuals with previous SARS-CoV-2 infection. All four vaccines conferred a high degree of protection against second symptomatic infections (ranging from 39.4% (CoronaVac) to 64.8% (BNT162b2)) and death (>80% for all two-dose vaccines) in previously infected individuals. Another study by Nordström et al. of Swedish nationwide registers also found that ‘hybrid immunity’ (from both infection and vaccination) provided additional protection compared to virus-induced immunity alone.
References
Original article
Cerqueira-Silva, T. et al. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(22)00140-2 (2022)
Nordström, P. et al. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(22)00140-2 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Flemming, A. Do individuals who have recovered from COVID-19 still benefit from being vaccinated?. Nat Rev Immunol 22, 275 (2022). https://doi.org/10.1038/s41577-022-00724-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41577-022-00724-1